Icu Medical Stock Price, News & Analysis

ICU Medical (Nasdaq: ICUI) will present at the J.P. Morgan 40^th Annual Healthcare Conference, scheduled from January 10-13, 2022. The presentation is set for January 12, 2022, at 10:30 a.m. PST (1:30 p.m. EST). Investors can access the live webcast on the company's website under the Investors tab. ICU Medical focuses on innovative products for infusion therapy and critical care, including IV smart pumps and closed system transfer devices. More details are available at www.icumed.com.

ICU Medical (Nasdaq:ICUI) reported a revenue increase of $336.1 million for the third quarter of 2021, up from $318.6 million in Q3 2020. The GAAP net income rose to $31.1 million, or $1.43 per diluted share, compared to $25.0 million, or $1.16 per diluted share, in the same quarter last year. Adjusted diluted EPS also increased to $2.07 from $1.90. The GAAP gross profit was $127.8 million with a gross margin of 38%. Notably, infusion consumables saw a significant increase, while IV solutions experienced a decline.

ICU Medical (Nasdaq:ICUI) announced its third quarter 2021 earnings release will occur on November 3, 2021, at approximately 4:00 p.m. ET. A conference call will follow at 4:30 p.m. ET, accessible via phone at (877) 407-3982 or through a webcast on the company's website. ICU Medical specializes in infusion therapy and critical care products, including IV smart pumps and safety software. The webcast will also be available for replay.

ICU Medical has announced its commitment to acquire Smiths Medical, expanding its infusion therapy capabilities with estimated combined revenues of $2.5 billion. The deal includes 2.5 million newly issued shares valued at $500 million and $1.85 billion in cash, alongside certain liabilities. Smiths will hold a 10% stake in ICU Medical post-transaction, with a board seat contingent on stock ownership. The acquisition is subject to regulatory approvals and is anticipated to close in H1 2022, strengthening ICU Medical's market position and enhancing customer service.

ICU Medical has announced a voluntary recall of one lot (2,112 units) of Aminosyn II, 15% due to visible particulate matter. This recall, effective nationwide, was initiated after fibers and proteinaceous material were detected in retain samples during routine inspections. The recalled product could pose health risks, including inflammation or severe blood clots. To date, no adverse events have been reported. The product is intended for nutritional support in patients unable to tolerate oral intake. Customers are advised to cease use and return the product.

ICU Medical reported second quarter 2021 revenue of $321.7 million, up from $303.4 million a year earlier. Gross profit rose to $123.5 million, with a gross margin of 38%, compared to 35% in Q2 2020. Net income was $28.4 million or $1.31 per diluted share, increasing from $18.9 million or $0.88 per share in the prior year. The company updated its 2021 guidance, adjusting expected adjusted EBITDA to $250 million to $260 million and adjusted diluted EPS to $6.80 to $7.20.

ICU Medical (Nasdaq:ICUI) will release its second quarter 2021 financial results on August 4, 2021, at approximately 4:00 p.m. ET. A conference call will follow at 4:30 p.m. ET, accessible at (866) 248-8441 or via webcast on the company's website. ICU Medical specializes in innovative medical products for infusion therapy and critical care applications, with a comprehensive portfolio including IV smart pumps and cardiac monitoring systems. For more information, visit www.icumed.com.

ICU Medical, Inc. (Nasdaq:ICUI) reported its first-quarter 2021 financial results, revealing revenues of $318.0 million, down from $328.6 million in Q1 2020. The GAAP gross profit for the quarter fell to $112.7 million, yielding a 35% gross margin, compared to 37% the previous year. Despite this decline, GAAP net income increased to $23.7 million or $1.09 per diluted share, up from $16.8 million or $0.78 per diluted share in Q1 2020. Adjusted diluted EPS decreased to $1.62 from $1.81.

ICU Medical, Inc. (Nasdaq:ICUI) announced its first quarter 2021 earnings release scheduled for May 6, 2021, at 4:00 p.m. ET, followed by a conference call at 4:30 p.m. ET. The call can be accessed via phone or streamed through the Company’s website. ICU Medical specializes in innovative medical products for infusion therapy and critical care, including IV smart pumps and cardiac monitoring systems. For more information, visit www.icumed.com.